Curis is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. Our most advanced drug candidate is CUDC-907, currently in Phase 2 clinical development for treatment of patients with MYC-altered DLBCL. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including the PD-L1/VISTA antagonist CA-170. Curis expects to file an IND and initiate clinical testing of CA-170 in cancer patients in the first half of 2016. As part of the Aurigene collaboration, Curis also licensed exclusive rights to oral small molecule antagonists of IRAK4 kinase, including the development candidate CA-4948. Curis expects to file an IND and initiate clinical testing of CA-4948 in 2016.
Our collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®; (vismodegib) for treatment of patients with advanced basal cell carcinoma, or BCC. Roche and Genentech are also continuing Erivedge®'s clinical development in less severe forms of BCC as well as in other diseases including in idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.
Our proprietary pipeline also includes two molecules for which we are seeking partners. These include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, which has completed a dose escalation Phase 1 clinical trial in patients with solid tumors or lymphoma. We also regained rights to our Heat Shock Protein 90, or HSP90, inhibitor from Debiopharm International S.A. and have re-designated this drug candidate as CUDC-305.
Jun 21, 2016
Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints
Jun 2, 2016
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.